{"id":"azd1722-salt-tablet","_chembl":{"chemblId":"CHEMBL1616414","moleculeType":"Small molecule","molecularWeight":"229.19"},"modality":"Small molecule","_dailymed":null,"_scrapedAt":"2026-03-28T04:57:47.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123697,"model":"claude-sonnet-4-5-20250929"},"description":"AZD1722 is an investigational small molecule developed by Ardelyx currently in Phase 1 clinical trials. The salt tablet formulation is being evaluated for safety and tolerability. Limited public information is available about its molecular target, mechanism of action, or specific therapeutic indications at this early stage of development.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT02226783","phase":"PHASE1","title":"D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2013-03","conditions":"Healthy Volunteers Food Interaction Study","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD1722 salt tablet","genericName":"AZD1722 salt tablet","companyName":"Ardelyx","companyId":"ardelyx","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}